Retatrutide, also known as LY3437943, is an engineered 39-amino-acid peptide based on the GIP peptide backbone that can activate three receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR)
Over time, experts discovered that GLP-1 drugs for weight loss, like Ozempic injections, Ozempic tablets, or Ozempic pills, also help with appetite control
This particular study looked at Mounjaros top competitor, Ozempic, and its heightened risk of gallbladder disease
Peptide in Berlin Berliner Forschungsstandort, EU-Bezugsquellen, HPLC- und COA-Anforderungen sowie Schengen-Versand nach Berlin
Symptoms may include rash, itching, or swelling
Daud et al